Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTASICKLE
2025-522005-38-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Iloprost with Placebo (2 arms). Primary endpoint: Mean opioid consumption in morphine equivalent mg/day over the 28 days following randomization. Planned start Mar 2026; status: authorised.
02
Drugs
iloprost
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2025-522005-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522005-38-00.